Third Quarter 2021 Financial Results Conference Call
For Fiscal Year Ending Dec 31, 2020
Receive updates straight into your inbox
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with central nervous system disorders. The company has five novel and differentiated drug development programs. OLINVYK™ is approved by the FDA. Please see Important Safety Information including Boxed Warning in the full prescribing information available at OLINVYK.com. The company has four investigational drug candidates including TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, TRV045 for diabetic neuropathic pain, and TRV027 for acute respiratory distress syndrome and abnormal clotting in COVID-19 patients.
955 Chesterbrook Blvd Suite 110 Chesterbrook, PA 19087
T: (610) 354-8840
LifeSci Advisors, LLC Dan Ferry Managing Director T: 617-430-7576 firstname.lastname@example.org